TP53 and acute myeloid leukemia: A combination of PCI-34051 (1), a selective HDAC8i, and cytarabine, the standard chemotherapeutic agent used in AML first-line therapy, was shown to have a synergistic effect in the reversion of myeloid leukaemia phenotype in AML cell line, promoting apoptosis in p53-expressing THP-1 cell line and cytostatic effect in HL60 cells [94].